DK3867244T3 - 4-pyrazin-2-ylmethylmorfolinderivater og anvendelse deraf som lægemiddel - Google Patents
4-pyrazin-2-ylmethylmorfolinderivater og anvendelse deraf som lægemiddel Download PDFInfo
- Publication number
- DK3867244T3 DK3867244T3 DK19786343.4T DK19786343T DK3867244T3 DK 3867244 T3 DK3867244 T3 DK 3867244T3 DK 19786343 T DK19786343 T DK 19786343T DK 3867244 T3 DK3867244 T3 DK 3867244T3
- Authority
- DK
- Denmark
- Prior art keywords
- ylmethylmorpholine
- pyrazin
- medicine
- derivatives
- ylmethylmorpholine derivatives
- Prior art date
Links
- JKLJHSTZIZURSR-UHFFFAOYSA-N 4-(pyrazin-2-ylmethyl)morpholine Chemical class C=1N=CC=NC=1CN1CCOCC1 JKLJHSTZIZURSR-UHFFFAOYSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18200943 | 2018-10-17 | ||
| PCT/EP2019/078027 WO2020079039A1 (en) | 2018-10-17 | 2019-10-16 | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3867244T3 true DK3867244T3 (da) | 2023-05-01 |
Family
ID=63878518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19786343.4T DK3867244T3 (da) | 2018-10-17 | 2019-10-16 | 4-pyrazin-2-ylmethylmorfolinderivater og anvendelse deraf som lægemiddel |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US11166958B2 (da) |
| EP (1) | EP3867244B1 (da) |
| JP (1) | JP7093468B2 (da) |
| KR (1) | KR20210079325A (da) |
| CN (1) | CN112888685B (da) |
| AR (1) | AR116711A1 (da) |
| AU (1) | AU2019362330B2 (da) |
| BR (1) | BR112021004993A2 (da) |
| CA (1) | CA3113308A1 (da) |
| CL (1) | CL2021000858A1 (da) |
| CO (1) | CO2021004612A2 (da) |
| CR (1) | CR20210184A (da) |
| DK (1) | DK3867244T3 (da) |
| DO (1) | DOP2021000069A (da) |
| EA (1) | EA202191014A1 (da) |
| EC (1) | ECSP21027009A (da) |
| ES (1) | ES2940184T3 (da) |
| FI (1) | FI3867244T3 (da) |
| HR (1) | HRP20230249T1 (da) |
| HU (1) | HUE061891T2 (da) |
| IL (1) | IL282142B2 (da) |
| JO (1) | JOP20210075A1 (da) |
| LT (1) | LT3867244T (da) |
| MA (1) | MA53898B1 (da) |
| MX (1) | MX2021004418A (da) |
| PE (1) | PE20211278A1 (da) |
| PH (1) | PH12021550834A1 (da) |
| PL (1) | PL3867244T3 (da) |
| PT (1) | PT3867244T (da) |
| RS (1) | RS63988B1 (da) |
| SA (1) | SA521421756B1 (da) |
| SG (1) | SG11202103806VA (da) |
| SI (1) | SI3867244T1 (da) |
| TW (1) | TWI828779B (da) |
| WO (1) | WO2020079039A1 (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3980401A1 (en) * | 2019-06-04 | 2022-04-13 | Boehringer Ingelheim International GmbH | Purine derivatives, as nr2b negative modulators and the use thereof as medicament, in particular for treating depressive disorders |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6495561B2 (en) | 1999-10-29 | 2002-12-17 | Merck & Co., Inc. | 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists |
| WO2002080928A1 (en) * | 2001-04-03 | 2002-10-17 | Merck & Co., Inc. | N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists |
| PL216636B1 (pl) * | 2001-07-24 | 2014-04-30 | Richter Gedeon Vegyészeti Gyár RT | Pochodne amidów kwasów karboksylowych, środek farmaceutyczny, sposób wytwarzania pochodnych amidów kwasów karboksylowych, sposób wytwarzania środka farmaceutycznego i zastosowanie pochodnych amidów kwasów karboksylowych |
| EP1959959B1 (en) * | 2005-12-06 | 2013-04-10 | Merck Sharp & Dohme Corp. | Morpholine carboxamide prokineticin receptor antagonists |
| WO2010088414A2 (en) * | 2009-01-28 | 2010-08-05 | Emory University | Subunit selective nmda receptor potentiators for the treatment of neurological conditions |
| WO2012128582A2 (en) * | 2011-03-23 | 2012-09-27 | Hyundai Pharm Co., Ltd. | A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME |
| EA025667B1 (ru) | 2012-10-18 | 2017-01-30 | Ф. Хоффманн-Ля Рош Аг | ПРОИЗВОДНЫЕ ЭТИНИЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ АКТИВНОСТИ РЕЦЕПТОРА mGluR5 |
| JP6577479B2 (ja) * | 2014-02-27 | 2019-09-18 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｎａｖ チャンネル阻害剤としてのヘテロ環化合物及びその使用 |
| US10913736B2 (en) | 2014-08-22 | 2021-02-09 | University Of Washington | Specific inhibitors of methionyl-tRNA synthetase |
| EP3362447B1 (en) * | 2015-10-14 | 2020-08-26 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
-
2019
- 2019-10-16 HU HUE19786343A patent/HUE061891T2/hu unknown
- 2019-10-16 PL PL19786343.4T patent/PL3867244T3/pl unknown
- 2019-10-16 CR CR20210184A patent/CR20210184A/es unknown
- 2019-10-16 MA MA53898A patent/MA53898B1/fr unknown
- 2019-10-16 CN CN201980067936.7A patent/CN112888685B/zh active Active
- 2019-10-16 PE PE2021000513A patent/PE20211278A1/es unknown
- 2019-10-16 KR KR1020217014924A patent/KR20210079325A/ko unknown
- 2019-10-16 CA CA3113308A patent/CA3113308A1/en active Pending
- 2019-10-16 JO JOP/2021/0075A patent/JOP20210075A1/ar unknown
- 2019-10-16 SG SG11202103806VA patent/SG11202103806VA/en unknown
- 2019-10-16 SI SI201930465T patent/SI3867244T1/sl unknown
- 2019-10-16 AR ARP190102937A patent/AR116711A1/es unknown
- 2019-10-16 JP JP2021520981A patent/JP7093468B2/ja active Active
- 2019-10-16 HR HRP20230249TT patent/HRP20230249T1/hr unknown
- 2019-10-16 FI FIEP19786343.4T patent/FI3867244T3/fi active
- 2019-10-16 BR BR112021004993-2A patent/BR112021004993A2/pt unknown
- 2019-10-16 MX MX2021004418A patent/MX2021004418A/es unknown
- 2019-10-16 EP EP19786343.4A patent/EP3867244B1/en active Active
- 2019-10-16 PT PT197863434T patent/PT3867244T/pt unknown
- 2019-10-16 EA EA202191014A patent/EA202191014A1/ru unknown
- 2019-10-16 ES ES19786343T patent/ES2940184T3/es active Active
- 2019-10-16 WO PCT/EP2019/078027 patent/WO2020079039A1/en active Application Filing
- 2019-10-16 DK DK19786343.4T patent/DK3867244T3/da active
- 2019-10-16 TW TW108137247A patent/TWI828779B/zh active
- 2019-10-16 RS RS20230140A patent/RS63988B1/sr unknown
- 2019-10-16 IL IL282142A patent/IL282142B2/en unknown
- 2019-10-16 AU AU2019362330A patent/AU2019362330B2/en active Active
- 2019-10-16 US US16/654,030 patent/US11166958B2/en active Active
- 2019-10-16 LT LTEPPCT/EP2019/078027T patent/LT3867244T/lt unknown
-
2021
- 2021-04-07 CL CL2021000858A patent/CL2021000858A1/es unknown
- 2021-04-13 CO CONC2021/0004612A patent/CO2021004612A2/es unknown
- 2021-04-14 PH PH12021550834A patent/PH12021550834A1/en unknown
- 2021-04-14 SA SA521421756A patent/SA521421756B1/ar unknown
- 2021-04-16 EC ECSENADI202127009A patent/ECSP21027009A/es unknown
- 2021-04-16 DO DO2021000069A patent/DOP2021000069A/es unknown
- 2021-08-27 US US17/458,631 patent/US20210393644A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3565550T3 (da) | Farmaceutiske sammensætninger omfattende meloxicam og rizatriptan | |
| DK3307707T3 (da) | Halogensubstituerede phenoxyphenylamidiner og anvendelsen deraf som fungicider | |
| DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
| DK3610005T3 (da) | Peptidligase og anvendelse deraf | |
| DK3607069T3 (da) | Produkter og sammensætninger | |
| DK3328843T3 (da) | 1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning | |
| DK3347472T3 (da) | Sammensætninger som indeholder cyp76ad1- clade polypeptider og anvendelse heraf. | |
| DK3786160T3 (da) | Pyridinderivater og terapeutiske anvendelser deraf som trpc6-inhibitorer | |
| DK3357513T3 (da) | Farmaceutisk sammensætning og anvendelse deraf | |
| DK3412660T3 (da) | Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme | |
| DK3640207T3 (da) | Molekularsi scm-15, syntesefremgangsmåde dertil og anvendelse deraf | |
| DK3514153T3 (da) | Pyrimidinforbindelse og farmaceutisk anvendelse deraf | |
| DK3532459T3 (da) | Lsd1-hæmmere og medicinske anvendelser deraf | |
| DK3347353T3 (da) | Pyrazolyl-substituerede heteroaryler og deres anvendelse som lægemidler | |
| DK3634377T3 (da) | Farmaceutisk formulering | |
| DK3268374T3 (da) | Kv1.3-inhibitorer og deres medicinske anvendelse | |
| DK3709978T3 (da) | Farmaceutisk oral formulering omfattende bakterier | |
| DK3768669T3 (da) | Piperazinazaspiroderivater | |
| DK3326463T3 (da) | Midesammensætning og anvendelse deraf som biologisk bekæmpelsesmiddel | |
| DK3797107T3 (da) | Heterokondenserede pyridonforbindelser og anvendelse deraf som idh- hæmmere | |
| DK3947375T3 (da) | Imidazolonylquinolinforbindelser og terapeutiske anvendelser deraf | |
| DK3412664T3 (da) | Heterocyklisk sulfonamidderivat og medicin indeholdende samme | |
| DK3386956T3 (da) | Fumagillolderivater og polymorfer deraf | |
| DK3666787T3 (da) | Antistoflægemiddelkonjugater som inkluderer hemiasterlinderivat | |
| DK3568396T3 (da) | Hidtil ukendte amino-imidazopyridinderivater som janus kinase-inhibitorer og farmaceutisk anvendelse deraf |